Assessment of the benefit of smaller eye drops

Not Applicable

• Conditions: Health Condition 1: H401- Open-angle glaucoma

• Registration Number: CTRI/2021/11/038002
• Lead Sponsor: anodropper Inc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 February 2022

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Patients with a recent diagnosis of primary open angle glaucoma (POAG) or ocular hypertension (OHT) and are not taking any ophthalmic medications for whom 0.5% timolol maleate would be prescribed as a first-line treatment

2. Participants must have corrected Snellen visual acuity of 6/60 or better in each eye

3. The baseline IOP should be between 21 and 35 mmHg as assessed by Goldmann applanation tonometry

Exclusion Criteria

1. A recent history (within the past 6 months) of ocular trauma, infection, or uveitis

2. Baseline IOP of < 21 mmHg

3. Baseline IOP of > 35 mmHg

4. History of cardiovascular, pulmonary, cerebrovascular, or chronic renal disease

5. History of borderline or uncontrolled systemic arterial hypertension

6. Use of any systemic α-agonist or β-blocker within 30 days of study commencement

7. History of receiving general anesthesia within the previous 30 days

8. Pregnant women and nursing mothers

Study & Design

• Study Type: Interventional
• Study Design: Not specified